Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry

Figures

• 

  Figure 1. Overview of ETNA–AF–China study enrolment by (A) geographical distribution of centres, (B) flowchart. *A patient may fulfil one or more exclusion criteria; †Patients with one or more of the following clinical factors were dose reduced: moderate or severe renal impairment (creatinine clearance (CrCl) ≤ 50 mL/min), body weight ≤ 60 kg or concomitant use of certain P-glycoprotein inhibitors listed in label and recorded at baseline. Not available category was considered on missing information for at least one potential dose reduction factor (i.e., renal impairment, body weight, P-glycoprotein inhibitors use), and no other reason fulfilled. CrCl, creatinine clearance; NVAF, nonvalvular atrial fibrillation.

• 

  Figure 2. Prevalence of doses according to (A) economic regions, and percentage of (B) previous using antiarrhythmics or antiplatelets, distribution of (C) age, (D) CHA2DS2–VASc score and (E) renal impairment as label recommendation. Renal impairment stages: Stage G1 eGFR ≥ 90 mL/min/1.73 m2, Stage G2 eGFR 60–90 mL/min/1.73 m2, Stage G3 eGFR 30–60 mL/min/1.73 m2, Stage G4 eGFR 15–30 mL/min/1.73 m2, Stage G5 eGFR < 15 mL/min/1.73 m2. eGFR, estimated glomerular filtration rate.

• 

  Figure 3. Dose of edoxaban prescribed to (A) frailty, (B) heart failure and (C) diabetes mellitus as label recommendation. DM, Diabetes mellitus.

• 

  Figure 4. Factors associated not in line with edoxaban label recommendation for (A) all doses, (B) 60 mg and (C) 30 mg in AF patients. BMI categories: normal 18.5–25, underweight < 18.5, overweight 25–30, obesity ≥ 30. Renal impairment stages: Stage G1 eGFR ≥ 90 mL/min/1.73 m2, Stage G2 eGFR 60–90 mL/min/1.73 m2, Stage G3 eGFR 30–60 mL/min/1.73 m2, Stage G4 eGFR 15–30 mL/min/1.73 m2, Stage G5 eGFR < 15 mL/min/1.73 m2. High–bleeding risk: based on one of the following: creatinine clearance (CrCl) < 50 mL/min, history of bleeding, HAS–BLED > 3. AF, Atrial fibrillation; BMI, Body mass index; CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; OR, Odds ratio; TIA, transient ischaemic attack; VKA, vitamin K antagonist.